sanofi
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Abstract 3802 Background: Deep-vein thrombosis (DVT) is a frequent complication of cancer and treatment of cancer. Among clinical…
Background: SoloSTAR® (SOL; sanofi-aventis, Paris, France) is a prefilled insulin pen device for the injection of insulin…
Abstract 1073
Poster Board I-95
Background: AVE5026 is a new generation hemisynthetic ultra-low molecular weight heparin…
Abstract 2097 Poster Board II-74 Background: Patients who undergo major orthopedic surgery are at significant risk of developing…
Abstract 1386 Poster Board I-408 Background: Medical patients with chronic medical illnesses are often at risk of VTE both in…
Background: As hospitalized cancer patients are at high risk of venous thromboembolism (VTE), evidence-based guidelines recommend…
Otamixaban, under development by sanofi-aventis, is a directly activated Factor X (FXa) inhibitor that is currently in phase IIb…
The 75th European Atherosclerosis Society congress, held in Prague, Czech Republic, at the end of April 2005, was a large, well…